Toyama Chemical Co Ltd is developing pazufloxacin (T-3761), an orally active synthetic quinolone antibiotic, which is awaiting registration following successful clinical trials that demonstrated its pharmacological similarities to tosufloxacin (Toyama Chemical Co) with respect to clinical efficacy, adverse effects and overall safety [272136]. As of June 2000, the company had filed an NDA for marketing approval in Japan [373027]. The company is also developing an injectable formulation, pazufloxacin mesylate (T-3762), which has entered phase III trials in Japan [228819]. There is a licensing agreement with Welfide Corp (formerly Yoshitomi/The Green Cross Corp) in Japan [228819].